Status:
UNKNOWN
Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis
Lead Sponsor:
University Hospital Muenster
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-65 years
Brief Summary
Treatment of acute relapsing multiple sclerosis (MS) has remained largely unaltered within past years. However, evidence defining the exact role of apheresis treatment in the therapeutic sequence is s...
Eligibility Criteria
Inclusion
- Signed informed consent form
- Diagnosis of relapsing-remitting multiple sclerosis according to 2017 revised McDonald-criteria
- Incomplete remission of relapse symptoms following initiation treatment with 1000mg/d intravenous methyl prednisolone
- Absence of fever or clinically apparent signs of infection
Exclusion
- Baseline EDSS score \>6.5 points
- Previous administration of less than 3x1000mg or more than 5x1000mg IVMPS for initiation treatment
- Known pregnancy or rejection to perform a pregnancy test (female patients only)
- Immunosuppressive treatment for conditions other than multiple sclerosis
- Ongoing neoplastic disorder or past neoplastic disorder within previous five years
- Known or newly diagnosed HIV-, HBV- or HCV-infection
- Regular intake of ACE inhibitor drugs
- Known bleeding disorders (including laboratory abnormalities such as: (I) platelet count\<50.000/µL; (II) international normalized ratio\>1.5, (III) activated prothrombin time\>50s) or intake of oral anticoagulant drugs
Key Trial Info
Start Date :
August 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT04450030
Start Date
August 1 2018
End Date
December 31 2020
Last Update
November 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology with Institute of Translational Neurology, University Hospital Muenster
Münster, North Rhine-Westphalia, Germany, 48149